Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

What abuse potential? Insys moves closer to marketing synthetic pot

  • Ed Silverman

By Ed Silverman March 28, 2017

Reprints
MARIJUANA
Insys Therapeutics will find it easier to market its synthetic version of marijuana. Yuri Cortez/AFP/Getty Images

File this under “How ironic!”

Last week, the Drug Enforcement Agency took a significant step that will make it easier for Insys Therapeutics to market its synthetic marijuana, which won regulatory approval last year to treat weight loss in AIDS patients and nausea caused by chemotherapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
New research may give geneticists a long-sought tool: a…
New research may give geneticists a long-sought tool: a targeted protein delivery device
British Columbia to bar Americans from buying Ozempic over…
British Columbia to bar Americans from buying Ozempic over supply concerns
FDA approves over-the-counter Narcan. Here’s what it means
FDA approves over-the-counter Narcan. Here’s what it means
Pharmalittle: WHO may add obesity drugs to essential medicines…
Pharmalittle: WHO may add obesity drugs to essential medicines list; monkey shortage may delay drug development

Recommended Stories